Sandoz and mAbxience agree on emicizumab biosimilar partnership

Partnershipemicizumab biosimilarPositive

AI Analysis

Summary

Sandoz and mAbxience have entered into a licensing, development, manufacturing and commercialisation agreement for an emicizumab biosimilar candidate to treat haemophilia A.

Importance:6/10

Sentiment:

0.50

biosimilarpartnershipemicizumabhaemophilia Alicensing agreement

Related Companies

$SDZ.SW

Read the original article

Published by Pharmaceutical Technology on September 21, 2026 7:38 AM

Read Original